TPST vs. ZNTL, EPRX, OGI, ADAP, SLN, ACTU, MCRB, TSVT, GNLX, and CKPT
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Zentalis Pharmaceuticals (ZNTL), Eupraxia Pharmaceuticals (EPRX), Organigram (OGI), Adaptimmune Therapeutics (ADAP), Silence Therapeutics (SLN), Actuate Therapeutics (ACTU), Seres Therapeutics (MCRB), 2seventy bio (TSVT), Genelux (GNLX), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical products" industry.
Tempest Therapeutics vs.
Tempest Therapeutics (NASDAQ:TPST) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Zentalis Pharmaceuticals' return on equity of -43.91% beat Tempest Therapeutics' return on equity.
Tempest Therapeutics received 40 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 65.79% of users gave Tempest Therapeutics an outperform vote while only 61.86% of users gave Zentalis Pharmaceuticals an outperform vote.
Tempest Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tempest Therapeutics currently has a consensus price target of $21.67, suggesting a potential upside of 2,488.61%. Zentalis Pharmaceuticals has a consensus price target of $8.24, suggesting a potential upside of 344.44%. Given Tempest Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tempest Therapeutics is more favorable than Zentalis Pharmaceuticals.
In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Tempest Therapeutics. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 0 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.89 beat Zentalis Pharmaceuticals' score of 0.31 indicating that Tempest Therapeutics is being referred to more favorably in the media.
Tempest Therapeutics has a beta of -1.83, meaning that its stock price is 283% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.
22.5% of Tempest Therapeutics shares are held by institutional investors. 4.7% of Tempest Therapeutics shares are held by company insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Tempest Therapeutics beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TPST) was last updated on 3/6/2025 by MarketBeat.com Staff
Free TPST Stock Alerts